Psychiatric Medication Management Online for Treatment-Resistant Patients

Not every antidepressant that did not work actually failed.

That distinction matters enormously for the patients who arrive at a new psychiatric platform carrying a treatment history that reads like a list of defeats: sertraline for six weeks, then escitalopram for two months, then a period of nothing because nothing seemed to be helping. They describe themselves as treatment-resistant. Sometimes their previous prescribers described them that way too. But when you ask the clinical questions, you find that neither trial reached a therapeutic dose. Neither was assessed at the right time point. Side effects were never managed. The medications were stopped before the clinical window for response had closed.

That is not treatment resistance. That is treatment that was never completed.

This is one of the most consequential misclassifications in outpatient psychiatry, and it is common. Not because prescribers are careless, but because the standard care structure, quarterly appointments with no between-visit monitoring and limited time for medication history review, creates the conditions for it. A patient who stopped sertraline at week four because of nausea, moved to a new city, and restarted care six months later with a new prescriber is not carrying a clinical verdict. They are carrying an incomplete trial history that may be misread as failure.

What Treatment-Resistant Depression Actually Means

Treatment-resistant depression is clinically defined as major depressive disorder that has not responded to at least two different antidepressant medications at adequate doses and for adequate duration, which means a minimum of six to eight weeks each. According to Cleveland Clinic and multiple clinical consensus frameworks, approximately 30% of people with major depressive disorder develop treatment-resistant depression.

That 30% figure is real and significant. But it also means 70% of people with MDD who feel like their medication has not worked may be experiencing something other than genuine treatment resistance. They may be experiencing under-dosed trials, inadequate duration, unmanaged side effects that caused early discontinuation, comorbid conditions that were not identified, or a lack of follow-up close enough to assess whether the medication was working.

A Delphi-method consensus from international experts published in Molecular Psychiatry confirmed that TRD requires failure of at least two adequate antidepressant trials, with less than 25% improvement in depressive symptoms, at appropriate doses and duration. Both conditions matter. A trial that ended at week four because of nausea that could have been managed with dose adjustment does not qualify as an adequate trial. Neither does one that stayed at the minimum starting dose because no one followed up.

How Medication Failure Gets Misdefined

The STAR*D trial, one of the largest real-world studies of antidepressant treatment, tracked outcomes through sequential medication steps for patients who did not respond to initial therapy. Rush et al. found that remission rates declined significantly with each sequential treatment step, from about 37% with the first medication to meaningfully lower rates at each subsequent step. This is why optimizing the first and second steps matters so much. Getting to the third or fourth step unnecessarily costs both time and clinical probability of remission.

There is a second, under-discussed problem. According to the American Family Physician, nonadherence to antidepressants is estimated between 20 and 50% of all patients, and it is particularly common in the early weeks of treatment when side effects are most prominent and clinical benefit has not yet developed. A patient who stops a medication at week three because of side effects they were not educated to manage has not failed that medication. They left before the trial was assessable. This is a system failure, not a medication failure.

Comorbid medical conditions compound this further. Hypothyroidism, chronic pain, cardiovascular disease, and sleep disorders can all contribute to depressive symptoms that do not respond to serotonergic agents alone. Cleveland Clinic notes that some patients diagnosed with treatment-resistant depression have an underlying undiagnosed health condition contributing to their depression. A medication change is the wrong next step when the correct next step is a medical workup.

What Online Psychiatric Medication Management Can Address

For patients who feel stuck on their current treatment, online psychiatric medication management is most valuable as a systematic re-evaluation platform, not as a mechanism to move faster through more medication switches. The clinical work is in the review, not the next prescription.

Dose Optimization

Many patients are on starting doses that were never titrated upward. A 50 mg dose of sertraline is a starting point, not a therapeutic target. If a prescriber never followed up to assess response and adjust, the patient may be experiencing partial benefit at a dose that was never intended to be final. A review of medication history often surfaces exactly this: adequate medications at inadequate doses for inadequate duration.

Prior Trial Review

Before assuming a medication should be changed, a clinician should ask why the previous one was stopped, whether side effects were managed, whether the dose was optimized, and whether the patient's symptom presentation at the time accurately reflected major depression as opposed to a contributing medical or situational factor. This review takes time and requires a clinical record with enough history to make sense of the sequence. Most brief follow-up appointments do not accomplish it.

Augmentation Strategies

For patients with genuine partial response to a first-line antidepressant, augmentation with a second non-controlled agent is an evidence-based next step. The American Psychiatric Association's clinical practice guidelines for major depressive disorder include augmentation options within the standard medication management framework. An online prescriber with a clear clinical picture can implement and monitor these strategies while tracking the patient's response with structured check-in data.

Structured Between-Visit Monitoring

This is the element most consistently missing from the treatment histories of patients who describe their medication as not working. Side effects that triggered early discontinuation were never caught because no one was checking. Partial responses that warranted dose adjustment went unaddressed because there was no follow-up mechanism between appointments. A platform with daily check-in data gives the prescriber something to work with: specific, timestamped reports of symptom severity, sleep, mood, and side effects that no quarterly appointment can replicate.

What Cannot Be Managed Online

Honesty on this point is part of what makes online psychiatric management trustworthy. Patients with genuine treatment-resistant depression who have completed two or more adequate antidepressant trials without response need access to interventional treatments. These include esketamine (Spravato), which was approved by the FDA in 2019 for treatment-resistant depression and requires in-person administration in a certified healthcare setting, as well as transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). These are not available through telehealth.

An online psychiatric medication management platform being used responsibly will identify when a patient's clinical picture warrants this referral and facilitate it explicitly. It should not become a mechanism for continuing ineffective treatment indefinitely. If you are not seeing response after two genuinely adequate trials of different antidepressant classes, the right next step is an in-person specialist evaluation, not a third trial.

How SiggyMD Reviews Medication Histories That Have Not Responded

When a patient arrives at SiggyMD with a history of medications that did not work, the intake AI captures the full treatment sequence: which medications were tried, at what doses, for how long, why they were stopped, and what was happening clinically when each decision was made. This information goes to a licensed prescriber alongside a comprehensive clinical assessment of the patient's current symptom picture and treatment goals.

The prescriber does not start from a blank page. They start from a structured clinical record that lets them ask the specific question: were these trials adequate? If not, the first recommendation may be to revisit and optimize rather than to switch again. If the trials were adequate and genuinely failed, the clinical picture supports a different recommendation, including referral to in-person interventional care when that is what the evidence indicates.

Daniel Montville, MD, of the SiggyMD clinical team, describes what this looks like in practice: "The most common thing I see when I review a history of failed antidepressants is that the failures were actually early discontinuations. Nausea in week two. A stressful life event in week three. A prescriber who was not available for follow-up. The medication may not have had a fair trial. The question I ask is not what to try next. It is whether we have actually tried what we have."

After the initial clinical review, the daily check-in structure provides the monitoring infrastructure that was missing from the prior treatment history. Dose titrations, side effect management, and response assessment happen with structured data, not from memory or a single quarterly visit.

What Members Are Saying

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Frequently Asked Questions

What Does Treatment-Resistant Depression Mean?

Treatment-resistant depression is defined as major depressive disorder that has not responded to at least two antidepressant medications at adequate doses and for adequate duration, typically six to eight weeks each, with less than a 25% reduction in depressive symptoms. Approximately 30% of people with major depressive disorder meet this threshold. The label should be applied only after both trials were genuinely adequate in dose, duration, and adherence, not after early discontinuations or under-dosed trials.

Can Online Psychiatrists Treat Treatment-Resistant Depression?

Online psychiatric medication management can address medication optimization, prior trial review, dose titration, augmentation strategies within non-controlled prescribing scope, and structured between-visit monitoring. For patients whose depression genuinely has not responded to two or more adequate antidepressant trials, interventional treatments like esketamine, TMS, and ECT require in-person specialized care and are not available through telehealth. A responsible online platform identifies when that referral is warranted and facilitates it explicitly.

How Many Antidepressants Should I Try Before Considering a Different Approach?

Clinical guidelines define treatment-resistant depression after two adequate trials of antidepressants from different pharmacological classes, each at therapeutic doses for at least six to eight weeks, with less than 25% symptom improvement. If your previous trials were stopped early due to side effects, inadequate dosing, or insufficient duration, those may not have been adequate trials. The clinical priority in that case is optimizing the trials you have rather than moving to the next step.

What Is Medication Augmentation in Psychiatry?

Augmentation refers to adding a second medication to an antidepressant that is producing partial benefit. Common strategies used in clinical practice include adding atypical antipsychotics or other agents alongside the primary antidepressant. It is an evidence-based option for patients with partial response and should be determined by a licensed prescriber who has access to your full treatment history and current clinical picture.

What If My Previous Provider Said I Was Treatment-Resistant?

A prior TRD label should prompt a comprehensive re-evaluation of whether previous trials met clinical criteria for adequacy. Many patients labeled treatment-resistant had trials stopped early, inadequately dosed, or complicated by unmanaged side effects or undiagnosed contributing medical conditions. If the prior trials were genuinely adequate, that review supports referral to appropriate interventional care. If they were not, the clinical path forward is different.

Is There Something Wrong with My Brain If Antidepressants Have Not Worked?

No. The most common reasons antidepressants do not produce lasting benefit are inadequate trial duration, under-dosing, unmanaged side effects that caused early discontinuation, comorbid conditions affecting treatment response, and insufficient monitoring between appointments. Genuine biological factors contributing to treatment resistance exist and are assessed after, not before, optimized standard treatment has been properly tried. If you feel your medication has not worked, the first clinical question is whether you received an optimized trial.

Bottom Line

Treatment-resistant depression is a real clinical entity affecting approximately 30% of people with major depressive disorder. It requires a treatment pathway beyond standard antidepressant trials. But most patients who feel their medication has not worked have not yet received an optimized standard trial.

The clinical value of comprehensive online psychiatric medication management for these patients is in the systematic review: not the next prescription. A platform that captures your full treatment history, audits whether prior trials were genuinely adequate, optimizes dosing with structured monitoring data, and identifies when interventional referral is appropriate serves a different, and more substantive, clinical function than one that simply moves to the next drug.

If you have been told your depression is treatment-resistant, the right question is whether that label was applied after two genuinely adequate trials, or after two abbreviated ones. The answer changes everything about what comes next.

Sources

1. Cleveland Clinic. Treatment-Resistant Depression: What It Is and Symptoms. Cleveland Clinic Health Library. Accessed May 2026.
2. Sforzini L, et al. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry. 2022;27(3):1286-1299.
3. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry. 2006;163(11):1905-1917.
4. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. APA. Accessed May 2026.
5. Gaynes BN, et al. Treatment-Resistant Depression. American Family Physician. 2009;80(2):167-172.
6. U.S. Food and Drug Administration. Drug Trials Snapshots: SPRAVATO (esketamine). FDA. Accessed May 2026.
7. Semahegn A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Systematic Reviews. 2020;9(1):17.
8. American Psychiatric Association. What Is Telepsychiatry? APA Patient Resources. Accessed May 2026.